Skip to main content

OncoLens brings multidisciplinary cancer care into focus

About OncoLens

What We Do

We envision a world where every cancer patient has access to the best possible minds, therapies and innovations in care – in time to make a difference.
Anju Mathew, Founder and CEO, OncoLens
With OncoLens, we bring together leading edge technology with the smartest minds in cancer care to deliver an innovative platform to support a new generation of cancer centers.
Better Patient Care
Clinician Empowerment
Enriched Care Planning
Clinical Decision Support

Our History

It’s hard to find someone in today’s world that has not been impacted by cancer, either themselves or a loved one. That was the case for OncoLens Co-Founder and CEO, Anju Mathew. Her personal family struggles with cancer brought to life the importance of a multidisciplinary approach to cancer care. As an experienced entrepreneur and technologist, she knew there had to be a better way.
Soon Anju began to collaborate with Dr. Lijo Simpson, a board-certified Hematologist/Oncologist and active participant in various cancer committees. Dr. Simpson understood first-hand the administrative burdens that a multidisciplinary approach to cancer care places on facilities. But he also understood the many advantages this approach brought to care teams and patients.
Together, they knew they could solve the challenges that were placing artificial limitations on the patients who could benefit from multidisciplinary cancer care. Together, they formed OncoLens.

Recent Timeline of OncoLens Milestones



  • Awarded SOC 2 Certification
  • Global Expansion to the Middle East
  • Molecular Module Released: Targeted Biomarker Treatment Planning


  • Collaborate Module Released: Secure Expert Opinions and Patient Referrals Beyond Health System Walls
  • Onboarded our 100th Cancer Center


  • OncoLens EMR Integration Solution Goes Live
  • Rapid COVID Response: Released Virtual Tumor Board Capabilities


  • Celebrated three-year anniversary of first customer, successfully completes CoC accreditation survey
  • Launched Survivorship care plan module


  • Venture Atlanta logo
    OncoLens selected as one among 30 showcase companies selected from hundreds of innovative young businesses from across the Southeast at Venture Atlanta
  • Dr. Simpson, OncoLens Chief Medical Officer, presents at ACCC Business Summit, in Washington D.C., establishing thought leadership in modern technology and clinical outcomes


  • Venture Atlanta logo
    Received Exceptional Research award at AONN, for work done in streamlining cancer conferences at Emory Decatur Hospital
  • Emory Decatur Nurse Navigators present results of utilization of OncoLens to streamline LDCT screening process at Oncology Nurse Navigator Conference, Austin TX
  • Market launch of Tumor Board Management module after successful deployment at Emory Decatur Hospital

Who We Serve


Lower cognitive load, ease coordination, access a single, comprehensive patient view, enable precision medicine, leverage clinical trial matching, and ease outreach for second opinions and insights

Nurse Navigators

Improve care coordination and patient outcomes, lower administrative demands and free-up time for patient care; manage patient tracking and survivorship care plans

Cancer Center Administrators

Improve the quality of care, ensure accreditation, and streamline referrals across the network

Cancer Registrars

Reduce time spent on data collection, case finding and conference planning, assign more cases per conference, and ease reporting to facilitate accreditation

OncoLens Welcomes Cross-Border Impact Ventures Fund as Capital Partner to Fuel International Growth

With an established network, OncoLens is on the cusp of creating an unprecedented global network of oncology providers that will open up access to cutting edge solutions for patients, enable global collaboration and intelligence sharing across the oncology ecosystem. We look forward to participating on this journey with the OncoLens team.
Donna Parr, Managing Director and Partner
Cross-Border Impact Ventures